The goal of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) Hematologic Malignancies and Bone Marrow Transplantation (HMBMT) Program is to improve the understanding and treatment of proliferative disorders that affect the lymphohematopoietic system. The Program is focused on three scientific aims that cross disease boundaries and bridge laboratory and clinical efforts: (1) targeting genetic and epigenetic alterations in hematologic malignancies, (2) studying stem cells in normal and neoplastic lymphohemato- poiesis, and (3) modulating immunoreactivity in hematologic malignancies and BMT. These thematic investigations extend from basic observations in the laboratory to clinical trials and from clinical observations back to laboratory investigation. Led by Richard F. Ambinder, M.D., Ph.D., Richard J. Jones, M.D., and Mark J. Levis, M.D., Ph.D., the Program consists of 32 Program members, 26 of whom have peer-reviewed funding, and an additional five junior faculty members have K awards. The Program has members with appointments in six departments. The National Cancer Institute (NCI) and other peer-reviewed funding of Program members totals $14.1 million total costs. The total number of publications by Program members is 575, of which 120 (21%) are Intra-Programmatic and 95 (17%) are Inter-Programmatic. Of these publications, 201 (35%) have external collaborations. Since the last review, the Program has continued to develop senior leaders through the retention and promotion of internal faculty members, such as Dr. Levis (leukemia), William Matsui, M.D. (multiple myeloma and cancer stem cells), and Patrick Brown, M.D. (pediatric leukemia), as well as the external recruitment of senior investigators, such as Kenneth Cooke, M.D., to lead the pediatric oncology effort in BMT. After developing the interdisciplinary/thematic focus of the faculty members in the Program, some of the major roles of Program leadership are prioritizing resources and ensuring that interactions are synergistic. Success in these endeavors has been recognized by continued funding for the Program Project Grant in BMT and the BMT Clinical Trials Network (CTN) Core Center Grant. In addition, the Program has played a vigorous role in the development and execution of relevant clinical trials, including national cooperative group endeavors of ECOG, COG, the BMT CTN and the AIDS Malignancy Consortium, with many examples of therapeutic strategies taken from the laboratory, through early clinical testing and into national multi-institutional trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-57
Application #
9944514
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
57
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Qiu, Xiang; Kumari, Gita; Gerasimova, Tatiana et al. (2018) Sequential Enhancer Sequestration Dysregulates Recombination Center Formation at the IgH Locus. Mol Cell 70:21-33.e6
Haffner, Michael C; Taheri, Diana; Luidy-Imada, Eddie et al. (2018) Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors. Proc Natl Acad Sci U S A 115:E8580-E8582
Nauman, Gina; Gray, Javaughn Corey; Parkinson, Rose et al. (2018) Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. Antioxidants (Basel) 7:
Ransome, Yusuf; Thurber, Katherine A; Swen, Melody et al. (2018) Social capital and HIV/AIDS in the United States: Knowledge, gaps, and future directions. SSM Popul Health 5:73-85
Kagohara, Luciane T; Stein-O'Brien, Genevieve L; Kelley, Dylan et al. (2018) Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. Brief Funct Genomics 17:49-63
De Silva, Ravindra A; Kumar, Dhiraj; Lisok, Ala et al. (2018) Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer. Mol Pharm 15:3946-3952
Bastos, Diogo A; Antonarakis, Emmanuel S (2018) CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. Expert Rev Mol Diagn 18:155-163
Afsari, Bahman; Guo, Theresa; Considine, Michael et al. (2018) Splice Expression Variation Analysis (SEVA) for inter-tumor heterogeneity of gene isoform usage in cancer. Bioinformatics 34:1859-1867
Zarif, Jelani C; Chalfin, Heather J; Pierorazio, Phillip M et al. (2018) Characterization of the Macrophage Infiltrate in a Case of Xanthogranulomatous Pyelonephritis. J Clin Urol 11:226-228
Rowe, Steven P; Luber, Brandon; Makell, Monique et al. (2018) From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol 12:1661-1672

Showing the most recent 10 out of 2393 publications